Early animal studies suggested that administration of monacolin K might be beneficial in experimental models of NAFLD by improving insulin sensitivity and decreasing obesity-related inflammation [13], but human studies are lacking. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.